Immediate and Long-term Results of Stenting of the Unprotected Left Coronary Artery Trunk in Patients with Stable Coronary Heart Disease

Objective. To assess the immediate and long-term results of stenting of the unprotected left coronary artery (LCA) trunk in patients, by using different types of drug-eluting stents.

Material and methods. The follow-up covered 282 patients who had undergone stenting of the unprotected LCA trunk. The mean follow-up was 34.6 [33.9; 35.3] months. The patients were divided into groups according to the type of a first-, second-, and third-generation implanted stent.

Results. The incidence of adverse cardiovascular events in the patients of Group 1 was significantly higher than in those in Groups 2 and 3 (29 and 7.6%, p<0.0001). The incidence of thrombosis of first-generation stents (7.0%) was significantly higher than that of second- and third-generation ones (1.6%) (p=0.02). The incidence of adverse cardiovascular events was comparable between Groups 2 and 3, despite a shorter duration of dual antiplatelet therapy in the third-generation stent group. The absence of stent postdilatation in the LCA trunk is an independent risk factor for adverse prognosis.

Conclusion. The use of second- and third-generation stents along with changes in the technical aspects of stenting of the unprotected LCA trunk leads to a substantial reduction in the risk of adverse cardiovascular events and allows the indications for intervention to be expanded in this patient category.

1. Arutyunyan G.K., Tereshchenko A.S., Kayraliev D.M., Merkulov E.V., Provatorov S.I., Samko A.N. Percutaneous coronary intervention for unprotected left main coronary artery stenosis in patients with stable ischemic heart disease. The evolution opinions. Neotlozhnaya Kardiologiya (Emergency Cardiology). 2017; 1: 25–33 (in Russ.).

2. Arutyunyan G.K., Merkulov E.V. The invasive treatment of coronary heart disease. In: Sergienko I.V., Ansheles A.A., Kukharchuk V.V. Dyslipidemia, atherosclerosis and coronary heart disease: modern aspects of pathogenesis, diagnosis and treatment. Moscow; 2018: 158–94 (in Russ.).

3. Stone P., Goldschlager N. Left main coronary artery disease: review and appraisal. Cardiovasc. Med. 1979; 4: 165–77.

4. Herrick J. Clinical features of sudden obstruction of the coronary arteries. JAMA. 1912; 59: 2015–20.

5. Conley M.J., Ely R.L., Kisslo J. The prognosis spectrum of left main stenosis. Circulation. 1978; 57: 947–52.

6. Fajadet J., Chieffo A. Current management of left main coronary artery disease. Eur. Heart J. 2012; 33: 36–50. DOI: 10.1093/eurheartj/ehr426

7. Patrick W.S., Marie-Claude M., Kappetein A.P., Colombo A., Holmes D.R., Mack M.J. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 2009; 360 (10): 961–72. DOI: 10.1056/NEJMoa0804626

8. Mohr F.W., Morice M.C., Kappetein A.P., Feldman T.E., Sta°hle E., Colombo A. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013; 381 (9867): 629–38. DOI: 10.1016/S0140-6736(13)60141-5

9. Windecker S., Kolh P., Alfonso F., Collet J.P., Cremer J., Falk V. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2014; 35: 2541–61.

10. Stone G.W., Sabik J.F., Serruys P.W. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N. Engl. J. Med. 2016; 375 (23): 2223–35. DOI: 10.1056/NEJMoa1610227

11. Mäkikallio T., Holm N.R., Lindsay M., Spence M.S., Erglis A., Menown I.B. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2017; 388 (100610): 2743–52.

12. Pandya B., Gaddam S., Raza M. Biodegradable polymer stents vs second generation drug eluting stents: a metaanalysis and systematic review of randomized controlled trials. World J. Cardiol. 2016; 8 (2): 240–6.

13. Danzi G.B., Piscione F. DES with bioabsorbable polymers, antiplatelet therapy and stent thrombosis. Turin: Edizioni Minerva Medica; 2012.

14. Jaryl Ng., Foin N. Over-expansion capacity and stent design model: an update with contemporary DES platforms. Intern. J. Cardiol. 2016; 221: 171–9.

15. Lassen J.F., Burzotta F., Banning A.P., Lefe`vre T., Darremont O., Hildick-Smith D. Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. EuroIntervention. 2018; 13 (13): 1540–53. DOI: 10.4244/EIJ-D-17-00622

16. Lemmert M.E., Oldroyd K., Barragan P., Lesiak M., Byrne R.A., Daemen J. et al. Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: rationale and study design of the prospective randomized multicenter IDEAL-LM trial. Am. Heart J. 2017; 187: 104–11. DOI: 10.1016/j.ahj.2017.02.015